Radiation device in the breast reduces complications for early stage breast cancer patientsApril 24, 2009A new study shows that the SAVI™ applicator, a small, expandable device inserted inside the breast to deliver partial breast irradiation, carries a low infection risk, a potential complication of such devices. The research, led by radiation oncologists and surgeons at the Moores UCSD Cancer Center and Fort Myers, Florida-based 21st Century Oncology, also indicates that other complications -- such as seromas, pockets of fluid that build with the use of internal radiation devices -- are unlikely to occur. That's good news for those women with early-stage breast cancer who opt to have such devices inserted for their radiation therapy after breast-sparing lumpectomy surgery, said Cate Yashar, MD, associate professor of radiation oncology at the UC San Diego School of Medicine and chief of breast and gynecological radiation services at the Moores UCSD Cancer Center. Their use is increasing, she added, noting that the Moores UCSD Cancer Center was one of the first medical facilities in the country to offer SAVI. SAVI, which consists of flexible catheters through which radiation is given, provides customized radiation therapy and minimizes exposure to healthy tissue after a woman has undergone a lumpectomy to remove a cancerous tumor. Radiation specialists sometimes decide to give women internal radiation -- a process called brachytherapy -- with the goal of giving concentrated doses of radiation to areas of concern while avoiding healthy tissue. In the study, researchers examined one-year follow-up data on 63 patients treated with the Food and Drug Administration-approved SAVI device. They found an infection rate that is less than half of the published rates associated with balloon brachytherapy methods, and rated overall cosmetic outcomes with SAVI as "excellent." The results will be presented at the American Society of Breast Surgeon's annual meeting in San Diego, April 24, 2009. In addition, physicians were able to use the device's many catheters to customize the radiation dose based on the woman's needs, greatly minimizing radiation to the heart, lungs, ribs and skin, likely resulting in fewer complications, Yashar said. To date, there have been no recurrences or formation of persistent seromas. "With a full year of follow-up, our research confirms previous findings that this device is safe and effective for radiation delivery, especially compared to other brachytherapy methods," said Yashar. "Without the ability to customize the dose, other devices can lead to complications, like persistent seroma and skin burns. This applicator was created to overcome these problems, and our research shows it has been successful." Breast brachytherapy is a form of Accelerated Partial Breast Irradiation (APBI). Lasting just five days, APBI offers a shorter course of radiation compared to the six weeks required with traditional whole breast irradiation. "SAVI has the most flexible dose modulation for single-entry APBI applicators and can sculpt the radiation dose to the size and shape of the tumor cavity and the patient's anatomy, even when only one to two millimeters from normal tissues," Yashar said. Without the technical limitations of other methods such as balloon brachytherapy, SAVI substantially increases the number of women who qualify for the benefits of APBI, she noted. University of California - San Diego |
|||||||||||||||||||||
| Related Brachytherapy Current Events and Brachytherapy News Articles Task force develops new radiation guidelines for brachytherapy Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient. Hormone therapy for prostate cancer patients with heart conditions linked to increased death risk Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death. Study shows seed implants a suitable prostate cancer treatment option for men of all ages Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient. Prostate cancer patients disease free after 5 years likely to be disease free after 10 years Prostate cancer patients who receive brachytherapy and remain free of disease for five years or greater are unlikely to have a recurrence at 10 years. External beam partial breast irradiation most cost-effective treatment External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI). Long-term study shows low oxygen levels in prostate tumors can predict recurrence Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer. Agent Orange exposure increases veterans' risk of aggressive recurrence of prostate cancer Veterans exposed to Agent Orange are at increased risk of aggressive recurrence of prostate cancer, researchers report. High dosage brachytherapy obtains excellent results in head and neck tumors High-dosage perioperative brachytherapy (applied within the surgical process) obtains excellent results in the treatment of head and neck tumours, at the same time as reducing the period of radiation. Early results favorable for 5-day radiation treatment of early stage prostate cancer Preliminary results show that a shortened course of radiation therapy for prostate cancer called stereotactic body radiation therapy (SBRT) provides good PSA response for early-stage prostate cancer and has the same side effects as other treatments. Family history of prostate cancer does not affect some treatment outcomes In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology. More Brachytherapy Current Events and Brachytherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||